Skip Navigation

Cardiovascular Research 1998 40(1):211-222; doi:10.1016/S0008-6363(98)00101-1
© 1998 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Poller, U.
Right arrow Articles by Brodde, O.-E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Poller, U.
Right arrow Articles by Brodde, O.-E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1998, European Society of Cardiology

Terbutaline-induced desensitization of human cardiac β2-adrenoceptor-mediated positive inotropic effects: attenuation by ketotifen

Ulrike Pollera, Birgit Fuchsb, Antje Gorfa, Jens Jakubetzb, Joachim Radkeb, Klaus Pönickea and Otto-Erich Broddea,*

aInstitute of Pharmacology and Toxicology, Martin-Luther-University of Halle-Wittenberg, D-06097 Halle/Saale, Germany
bDepartment of Anaesthesiology, Martin-Luther-University of Halle-Wittenberg, D-06097 Halle/Saale, Germany

* Corresponding author: Tel.: +49-345-557 1773; Fax: +49-345-557 1835.

Background: In patients with chronic heart failure cardiac β1-adrenoceptors are desensitized whereas β2-adrenoceptors are only marginally affected. The mechanism underlying this differential regulation is not known. Objectives: To find out whether or not human cardiac β2-adrenoceptors might be ‘resistant’ to agonist-induced desensitization and whether or not the antiallergic drug ketotifen might attenuate possible desensitization. Methods: We investigated, in a single blinded, randomised, placebo-controlled, cross-over study of ten healthy male volunteers (mean age, 25.3±0.7 years), the effects of two weeks treatment with the β2-adrenoceptor agonist terbutaline (3x5 mg/day p.o.) with and without simultaneous treatment with ketotifen (2x1 mg/day p.o. for three weeks) or placebo on β-adrenoceptor-mediated cardiovascular effects. Cardiovascular effects were assessed as isoprenaline (3.5–35 ng/kg/min)- and terbutaline (25–150 ng/kg/min)-infusion-induced increases in heart rate and systolic blood pressure, decreases in diastolic blood pressure and shortening of the systolic time intervals (STIs), heart rate corrected duration of electromechanical systole (QS2c) and pre-ejection period (PEP; as a measure of inotropism). Results: Ketotifen did not significantly affect basal haemodynamics in the volunteers. Isoprenaline- and terbutaline-infusion caused dose-dependent increases in systolic blood pressure and heart rate, decreases in diastolic blood pressure and shortening of QS2c and PEP, whereby isoprenaline effects were more pronounced. After two weeks of treatment with terbutaline p.o., isoprenaline- and terbutaline-infusion-induced increases in heart rate, shortening of QS2c and PEP were significantly reduced whereby terbutaline-infusion effects were markedly more attenuated than isoprenaline-infusion effects. Ketotifen significantly reduced terbutaline p.o. treatment-induced attenuation of all terbutaline-infusion effects (largely β2-adrenoceptor-mediated) and the isoprenaline-infusion-induced increase in heart rate 1- and β2-adrenoceptor-mediated), but did not (or only marginally) affect reduction in isoprenaline-induced shortening of QS2c and PEP (largely β1-adrenoceptor-mediated). Conclusion: Human cardiac β2-adrenoceptors are not ‘resistant’ to agonist-induced desensitization: Ketotifen might prevent such β2-adrenoceptor-agonist-evoked desensitization.

KEYWORDS Human cardiac β1-adrenoceptors; Human cardiac β2-adrenoceptors; Positive inotropic effect; Desensitization; Terbutaline; Ketotifen


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
N. Elia, M. Tapponnier, M. A. Matthay, J. Hamacher, J.-C. Pache, M.-A. Brundler, M. Totsch, P. De Baetselier, L. Fransen, N. Fukuda, et al.
Functional Identification of the Alveolar Edema Reabsorption Activity of Murine Tumor Necrosis Factor-{alpha}
Am. J. Respir. Crit. Care Med., November 1, 2003; 168(9): 1043 - 1050.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
H. Bruck, K. Leineweber, A. Ulrich, J. Radke, G. Heusch, T. Philipp, and O.-E. Brodde
Thr164Ile polymorphism of the human {beta}2-adrenoceptor exhibits blunted desensitization of cardiac functional responses in vivo
Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H2034 - H2038.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. H. Au, E. M. Udris, V. S. Fan, J. R. Curtis, M. B. McDonell, and S. D. Fihn
Risk of Mortality and Heart Failure Exacerbations Associated With Inhaled {beta}-Adrenoceptor Agonists Among Patients With Known Left Ventricular Systolic Dysfunction
Chest, June 1, 2003; 123(6): 1964 - 1969.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
O.-E. Brodde, R. Buscher, R. Tellkamp, J. Radke, S. Dhein, and P. A. Insel
Blunted Cardiac Responses to Receptor Activation in Subjects With Thr164Ile {beta}2-Adrenoceptors
Circulation, February 27, 2001; 103(8): 1048 - 1050.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
O.-E. Brodde and M. C. Michel
Adrenergic and Muscarinic Receptors in the Human Heart
Pharmacol. Rev., December 1, 1999; 51(4): 651 - 690.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.